Search Blog
Categories
November 2013
M T W T F S S
« Oct   Dec »
 123
45678910
11121314151617
18192021222324
252627282930  

Tags

GOGO, CLDX, VPHM and ARNA Added to NASDAQ Active Stock Watch List at EPR

admin

By Equity Profile Report

New York, NY – (ACCESSWIRE) – 11/11/2013 – Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Gogo Inc. (NASDAQ:GOGO), Celldex Therapeutics, Inc. (NASDAQ:CLDX), ViroPharma Inc. (NASDAQ:VPHM), and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA).

Gogo Inc. (NASDAQ:GOGO) a company that provides in-flight Internet connectivity and wireless in-cabin digital entertainment solutions in the United States and internationally is currently up (+18.99%) on 1,444,956 shares traded after Gogo Announced Third Quarter 2013 Results and Raises Full Year Guidance. Gogo Inc. (NASDAQ:GOGO) is currently up (+135.22%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll. 

To find out what other Investors are saying about Gogo Inc. (NASDAQ:GOGO)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=GOGO&SubId=AW 

Celldex Therapeutics, Inc. (NASDAQ:CLDX) a biopharmaceutical company that focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States is currently up (+2.42%) on 539,802 shares traded after Celldex Therapeutics announced publication of preliminary data from the Phase 2 ReACT study. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is currently up (+432.87%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll. 

To find out what other Investors are saying about Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=CLDX&SubId=AW 

ViroPharma Inc. (NASDAQ:VPHM) a biotechnology company that develops and commercializes therapeutic products that address serious diseases in the United States and internationally is currently up (+25.47%) on 33,421,122 shares traded after ViroPharma announced to be acquired by Shire for $50 per share. ViroPharma Inc. (NASDAQ:VPHM) is currently up (+123.55%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll. 

To find out what other Investors are saying about ViroPharma Inc. (NASDAQ:VPHM)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=VPHM&SubId=AW 

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) a biopharmaceutical company that engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases is currently up (+7.43%) on 2,671,259 shares traded after Arena Pharmaceuticals’ CEO Discussed Q3 2013 Results. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is currently up (+27.16%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll. 

To find out what other Investors are saying about Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=ARNA&SubId=AW Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures. 

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com